AR-13503_product_DataBase

Bioactivity	AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice[1][2].
Invitro	AR-13503 (16 小时) 抑制人脐静脉内皮细胞 (HUVEC) 管的形成，IC50 为 21 nM[1]。AR-13503 (400 nM; 5 天) 以剂量依赖的方式减少脉络膜的发芽面积[1]。AR-13503 (400 nM; 2 周) 以剂量依赖的方式增强猪主要 RPE 屏障功能[1]。
In Vivo	AR-13503 (1.25 mg/kg；腹腔注射；每天 1 次，共 5 天) 与 Aflibercept (HY-108801) 有协同作用，显著降低了异常新生血管 (NV) 形成[1]。 Animal Model:
Name	AR-13503
CAS	1254032-16-0
Formula	C19H19N3O2
Molar Mass	321.37
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Ding J, et al. ROCK/PKC inhibitor AR-13503 inhibits angiogenesis and protects the barrier function of retinal pigment epithelium[J]. Investigative Ophthalmology & Visual Science, 2018, 59(9): 205-205. [2]. Carbajal K, et al. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy[J]. Investigative Ophthalmology & Visual Science, 2018, 59(9): 200-200.

PeptideDB